Carregant...
Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Science Inc
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/ https://ncbi.nlm.nih.gov/pubmed/17166187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|